Jennifer Champoux net worth and biography

Jennifer Champoux Biography and Net Worth

Jen joined Monte Rosa with over 15 years of operations experience in the biotech industry, including site operations, strategic planning, finance, communications, and culture & employee engagement. Prior to joining Monte Rosa, Jen was Executive Director of Operations at H3 Biomedicine where she led the operations, communications, and finance operations teams. She previously worked at Novartis Institutes for Biomedical Research where she led operations for the Discovery Chemistry group in Cambridge. Jen started her career in several pharmaceutical development functions, including process chemistry, program management, and clinical operations at Merck and Array BioPharma. Jen holds a M.S. in chemistry from Indiana University.

What is Jennifer Champoux's net worth?: The estimated net worth of Jennifer Champoux is at least $1.08 million as of May 27th, 2026. Champoux owns 62,371 shares of Monte Rosa Therapeutics stock worth more than $1,082,761 as of June 4th. This net worth evaluation does not reflect any other investments that Champoux may own. Learn More about Jennifer Champoux's net worth.
How do I contact Jennifer Champoux?: The corporate mailing address for Champoux and other Monte Rosa Therapeutics executives is , , . Monte Rosa Therapeutics can also be reached via phone at 617-949-2643 and via email at [email protected]. Learn More on Jennifer Champoux's contact information.
Has Jennifer Champoux been buying or selling shares of Monte Rosa Therapeutics?: During the last quarter, Jennifer Champoux has sold $43,500.00 of Monte Rosa Therapeutics stock. Most recently, Jennifer Champoux sold 2,175 shares of the business's stock in a transaction on Wednesday, May 27th. The shares were sold at an average price of $20.00, for a transaction totalling $43,500.00. Following the completion of the sale, the chief operating officer now directly owns 62,371 shares of the company's stock, valued at $1,247,420. Learn More on Jennifer Champoux's trading history.
Who are Monte Rosa Therapeutics' active insiders?: Monte Rosa Therapeutics' insider roster includes Jennifer Champoux (COO), Philip Nickson (Insider), and Markus Warmuth (CEO). Learn More on Monte Rosa Therapeutics' active insiders.
Are insiders buying or selling shares of Monte Rosa Therapeutics?: During the last twelve months, insiders at the sold shares 7 times. They sold a total of 44,791 shares worth more than $840,589.95. The most recent insider tranaction occured on May, 27th when COO Jennifer Champoux sold 2,175 shares worth more than $43,500.00. Insiders at Monte Rosa Therapeutics own 6.4% of the company. Learn More about insider trades at Monte Rosa Therapeutics.
Information on this page was last updated on 5/27/2026.

Jennifer Champoux Insider Trading History at Monte Rosa Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
5/27/2026	Sell	2,175	$20.00	$43,500.00	62,371

Jennifer Champoux Buying and Selling Activity at Monte Rosa Therapeutics

Monte Rosa Therapeutics Company Overview

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $17.36

$17.09

$18.07

50 Day Range

MA: $18.37

$14.72

$20.98

2 Week Range

Now: $17.36

$4.12

$25.77

Volume

729,624 shs

Average Volume

1,314,825 shs

Market Capitalization

$1.47 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.6